We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Skinbiotherapeutics Plc | LSE:SBTX | London | Ordinary Share | GB00BF33H870 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 9.25 | 9.00 | 9.50 | 9.25 | 9.25 | 9.25 | 86,025 | 08:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | 132k | -2.84M | -0.0163 | -5.67 | 16.1M |
From Apr 2019 to Apr 2024
TIDMSBTX
RNS Number : 7866H
SkinBioTherapeutics PLC
19 November 2018
SkinBioTherapeutics plc
(the "Company")
Result of AGM
SkinBioTherapeutics plc (AIM: SBTX), announces that at the Company's Annual General Meeting, held earlier today, all resolutions were duly passed.
For further information, please contact:
SkinBioTherapeutics plc Tel: +44 (0) 161 468 2760 Dr. Catherine O'Neill, CEO Doug Quinn, CFO Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20 7213 0880 Adviser) Tony Rawlinson / Sandy Jamieson / Richard Nash Turner Pope Investments (Joint Tel: +44 (0) 20 3621 4120 Broker) Ben Turner / James Pope Northland Capital Partners (Joint Tel: +44 (0) 20 3861 6625 Broker) Dugald Carlean Instinctif Partners Tel: +44 (0) 20 7457 2020 Melanie Toyne-Sewell / Deborah SkinBio@instinctif.com Bell
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix(R), is based upon discoveries made by CEO Dr. Catherine O'Neill and Professor Andrew McBain.
SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix(R) platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix(R) platform has beneficial attributes applicable to each of these areas.
SkinBioTherapeutics received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix(R). The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix (AIM: OPTI).
The Company joined AIM in April 2017 concurrent with raising GBP4.5 million from a placing of new ordinary shares.
The Company is based in Manchester, UK. For more information, visit www.skinbiotherapeutics.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
RAGFKCDDBBDDPDD
(END) Dow Jones Newswires
November 19, 2018 07:30 ET (12:30 GMT)
1 Year Skinbiotherapeutics Chart |
1 Month Skinbiotherapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
